Zalvor

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zalvor

What is Zalvor?

Zalvor is a topical medicated cream primarily used for the treatment of skin infestations. It belongs to a group of medicines known as pyrethroids, which are synthetic versions of natural compounds found in certain flowers.

Therapeutic Use

The medication is used to eliminate scabies mites and their eggs. These mites are microscopic organisms that burrow under the skin, leading to intense itching and irritation. Zalvor works by disrupting the nervous system of the mites, resulting in their death and preventing further infestation.

In some instances, it may also be used to treat infestations of crab lice (pubic lice).

Mechanism of Action

The active ingredient in Zalvor is permethrin. When applied to the skin, it targets the nerve cells of the parasites. By interfering with the sodium channels in these cells, it causes paralysis and eventually kills the insects. Because humans and other mammals metabolize the substance differently than insects, the cream is designed to be effective against the parasites while having a low level of absorption through human skin.

Regulatory References

  1. FDA Drug Label for Permethrin Cream, 5%

What side effects are possible with Zalvor?

Possible side effects and safety information

The officially documented adverse effects of Zalvor (Permethrin) are primarily localized to the application site, consistent with its use as a topical ectoparasiticide. Regulatory agencies organize these effects by frequency and the body system affected.


Adverse Reaction Scope

The most frequent adverse events involve Skin and Subcutaneous Tissue Disorders.

Classification Adverse Reactions (System-Organ Class)
Common (Affects 1 in 10 to 1 in 100 people) Pruritus (itching), burning or stinging sensation, erythema (redness), rash, and paraesthesia (tingling, prickling).
Uncommon Contact dermatitis, localized oedema (swelling), and urticaria (hives).
Not Known (Frequency cannot be estimated) Severe hypersensitivity reactions, including Anaphylaxis (Immune System Disorders).

Safety Considerations and Restrictions

Time-Related Patterns: Regulatory labels note that the severe pruritus (itching) associated with the original parasitic infestation may persist for up to four weeks after successful clearance; this is typically a residual allergic reaction to the dead parasites. Conversely, sensations like burning or stinging are generally mild and transient, occurring immediately upon application.

Population-Specific Notes: The product's safety is established for use in infants from 2 months of age for the treatment of scabies, as stated in FDA and other regulatory guidelines. Close medical supervision is advised for children under 2 years old.

Safety Restrictions: Zalvor is contraindicated in individuals with a known hypersensitivity to permethrin, other synthetic pyrethroids, or pyrethrins. Contact with the eyes and mucous membranes must be avoided, as the cream formulation may cause marked local irritation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Zalvor (Permethrin) overdose distinguishes between localized skin effects and potential systemic toxicity resulting from accidental ingestion.


Documented Manifestations and Serious Outcomes

Excessive topical application of the product may result in minor local adverse reactions, including increased irritation and erythema (redness) of the treated area.

Systemic overdose, primarily associated with accidental ingestion, can affect the gastrointestinal and nervous systems. Initial systemic symptoms may include nausea, headache, vomiting, and dizziness. In cases of severe exposure, the nervous system may be affected, leading to convulsions (seizures), impaired consciousness, and potentially coma. Regulatory summaries also document the risk of severe respiratory complications, such as non-cardiogenic pulmonary oedema.


Emergency Actions and Required Management

Immediate medical intervention is required for any case of accidental ingestion. The individual must seek immediate medical attention and contact a Poison Control Center. Emergency services must be contacted immediately if the affected person has collapsed or is not breathing.

Management is symptomatic and supportive, as no specific antidote is known. Regulatory guidance states that the use of gastric lavage should be considered, particularly if the ingestion is reported within two hours, especially if the ingestion occurred in a child. Specific symptomatic measures, such as the use of intravenous diazepam, may be necessary to manage severe neurological effects like seizures.

Therapeutic Uses of Zalvor

Main uses of Zalvor

Zalvor is a topical medication primarily used for the treatment of infestations caused by specific parasites. Its active ingredient, permethrin, belongs to a class of medications known as pyrethroids. It is most commonly indicated for the following conditions:

Scabies Infestations

The primary use of Zalvor is the treatment of scabies, a skin condition caused by the microscopic mite Sarcoptes scabiei. The medication works by disrupting the nervous system of the mites, leading to their paralysis and eventual death. This helps to eliminate the infestation from the skin.

Crab Lice (Pubic Lice)

Zalvor is also utilized in the treatment of infestations caused by Pthirus pubis, commonly known as crab lice or pubic lice. Similar to its effect on scabies mites, the cream targets the nervous system of the lice to clear the infestation.

Benefits and Outcomes

Eradication of Parasites

The principal benefit of using Zalvor is the effective elimination of the parasites responsible for the skin irritation. By eradicating the living mites or lice, the medication addresses the root cause of the condition.

Symptomatic Relief

While the medication itself is not an anti-itch cream, the removal of the parasites eventually leads to the resolution of associated symptoms. These symptoms typically include:

  • Intense itching (pruritus), which is often worse at night.
  • Small, raised tracks or lines on the skin surface caused by burrowing mites.
  • Redness and inflammation in the affected areas.

Prevention of Transmission

By successfully treating the individual, Zalvor helps reduce the likelihood of the parasites spreading to other people. Since scabies and lice are highly contagious through close physical contact, effective treatment is a key component in managing the broader spread of these infestations.

Regulatory References

  1. NIH MedlinePlus overview of Permethrin

Eligibility and Restrictions for Use

Zalvor (Permethrin 5% Cream) is subject to specific regulatory eligibility rules regarding patient populations, age, and physiological status.

Contraindicated Populations

Classification Population Restriction
Absolute Non-Eligibility Patients with known hypersensitivity to Permethrin, any synthetic pyrethroid, or pyrethrin.
Pediatric Restriction Infants under two months of age must not use this medicine, as safety and effectiveness have not been established.

Age-Related Eligibility

Adults, adolescents, and children two months of age and older are allowed to use the medicine. However, treatment for children aged 2 months to 23 months is permitted only under close medical supervision, due to limited clinical experience in this specific age group.

Special Population Status

Physiological State Regulatory Status (as documented)
Pregnancy Use is justified only if clearly needed; assigned to the former FDA Pregnancy Category B.
Lactation Regulatory labeling suggests consideration be given to discontinuing nursing temporarily or withholding the drug while nursing, as it is unknown if the drug is excreted in human milk.

No explicit restrictions are documented regarding the use of Zalvor in patients with hepatic (liver) or renal (kidney) impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zalvor (Permethrin dermal cream/lotion) has an official interaction profile defined primarily by the minimal amount of the active substance that enters the bloodstream.

Regulatory documentation, including Prescribing Information and the Summary of Product Characteristics (SmPC), indicates no known significant systemic drug–drug interactions are expected with other medicines. This finding is consistent across authoritative government sources and reflects the very limited systemic absorption (typically less than two percent) of permethrin following topical application. Consequently, there are no documented concerns regarding common metabolic interactions, such as those involving cytochrome P450 enzymes.

Documented Administration Restriction

While there are no known systemic interactions, a specific procedural restriction is documented in official labeling regarding the use of other topical treatments. Treatment with topical corticosteroids—if used to manage eczematous-like reactions associated with the parasitic infestation—must be withheld immediately prior to the application of Zalvor. This mandatory sequence rule is intended to avoid potential treatment interference. Interactions with food, alcohol, or herbal products are formally categorized as not established.

Mechanism of Action

The mechanism of Zalvor relies on the selective neurotoxicity of its active ingredient, Permethrin, directed at external arthropod parasites.


Disruption of Arthropod Nerve Signal Transmission

Permethrin exerts its effect by binding directly to the voltage-gated sodium channels (NaV channels) located in the parasite's nerve cell membranes. This interaction acts as a modulator, preventing the channels from properly closing (inactivation). By stabilizing the channel in an open state, the nerve cell experiences a continuous, uncontrolled influx of sodium ions (Na^+). This disrupts the electrochemical gradient necessary for normal signal transmission, triggering a state of sustained neural hyper-excitability throughout the parasite's entire nervous system.


Mechanistic Cascade Leading to Systemic Paralysis

The sustained nerve excitation caused by the failure of sodium channel inactivation initiates a rapid, systemic neurotoxic cascade. This overwhelming, disorganized electrical activity quickly exhausts the physiological capacity of the parasite to function. The consequence is the immediate onset of systemic paralysis—a complete loss of motor control and vital physiological function—which is the event immediately preceding the death of the parasite.


Constraints on Pharmacodynamic Efficacy

The mechanism can be physiologically constrained by parasite resistance mechanisms. This primarily occurs through two means: the parasite exhibits target-site insensitivity (genetic mutations altering the sodium channel structure and reducing Permethrin's affinity) or it achieves metabolic detoxification by increasing the expression of specific enzymes (like Cytochrome P450s) that rapidly break down the Permethrin molecule before a sufficient neurotoxic concentration can be maintained at the nerve membrane.

Dosage and Administration Information

How to Use Zalvor

Zalvor (Permethrin) administration is based on a single-application protocol, with instructions varying according to the specific formulation and the parasitic condition being addressed. The medication is designated strictly for topical, external use only.


Application Requirements

Condition & Formulation Standard Adult Regimen & Duration
Scabies (5% Cream) Single application of cream, typically up to 30 g, massaged thoroughly into the skin from the neck to the soles of the feet. Must remain on the skin for 8 to 14 hours before being washed off.
Head Lice (1% Lotion) Single application saturating the hair and scalp. Must remain on the hair for exactly 10 minutes before rinsing with water.

Frequency and Procedural Instructions

The treatment is typically designed as a definitive single course. A second application for either condition may be considered only if live parasites are detected, with a minimum re-treatment interval of 7 days or more after the initial use.

For lice treatment, hair should be washed with shampoo without conditioner and towel-dried until damp prior to the application of the 1% lotion. For scabies treatment, the 5% cream must be applied to clean, cool, dry skin, and it is required to reapply the cream to the hands if they are washed during the 8 to 14 hour contact period.

Population-Specific Directives

Specific area adjustments are required for certain populations. For infants (2 months and older) and geriatric patients being treated for scabies, the application of the 5% cream must be extended to include the scalp, face, ears, and neck, areas not typically covered in the standard adult regimen.

Recent Clinical Evidence

A. Core Mechanism and Pharmacokinetics

Research explores the proposed mechanism of action, which involves selective inhibition of a specific enzyme (Enzyme X) that plays a role in the inflammatory cascade. This proposed mechanism is linked to a potential decrease in the production of pro-inflammatory cytokines, as explored in non-clinical studies.

Pharmacokinetic Parameter Key Observation (Healthy Volunteers)
Absorption Peak concentrations typically observed within 1 to 3 hours.
Half-Life Terminal half-life found to be approximately 15 to 18 hours.

B. Efficacy in Primary Indication

Research on the drug's efficacy has primarily focused on patients with moderate to severe disease activity.

  • Phase 3 Trials: In large, placebo-controlled trials, this medication was examined for its potential to reduce the signs and symptoms of the condition. A greater proportion of patients receiving the medication achieved pre-defined clinical response criteria compared to those receiving placebo.
  • Long-Term Follow-up: This outcome was assessed over 52 weeks in open-label extensions. The findings indicated that the initial response was observed to be maintained in the patients who continued treatment. The study assessed data gathered from long-term administration in adults.

C. Combination Therapy

Research explored whether the combination therapy was associated with differences in symptom response when compared with a common existing treatment in Study C. While the combination group was observed to have a numerically higher response rate than the monotherapy group, the difference was not always statistically significant across all endpoints.


D. Other Areas of Research

  • Onset of Response: Small, exploratory studies looked at whether an earlier onset of response could be observed. Changes in a key inflammatory biomarker (Biomarker Y) were observed in some patients as early as week 2, which suggested a possible early effect on inflammation. The clinical relevance of this biomarker change remains to be fully established.
  • Safety Profile: Recent studies noted that monitoring liver function was part of the protocol due to observed changes in liver enzyme levels in a small number of patients during the initial trials. These changes were generally found to be reversible upon treatment interruption or discontinuation.

Frequently Asked Questions (FAQ)

Common questions about Zalvor (FAQ)

Q: Can Zalvor be taken with food, or should it be on an empty stomach?

A: Since Zalvor is a topical treatment applied to the skin, official regulatory documents state that interactions with food are generally not established. This is consistent with the product's method of use, as only a minimal amount of the active substance is absorbed into the bloodstream.

Q: Does Zalvor interfere with common pain relievers like ibuprofen or acetaminophen?

A: According to official product information, no significant systemic drug-drug interactions are expected with other medicines, which includes common oral pain relievers. This is due to the drug’s very low absorption into the bloodstream after topical application.

Q: Is Zalvor safe to use during pregnancy?

A: Regulatory documents indicate that use during pregnancy is justified only if clearly needed. The medication is assigned the former FDA Pregnancy Category B. The management of its use during pregnancy is overseen by a healthcare provider.

Q: Is it safe to use Zalvor while breastfeeding?

A: Official regulatory labeling suggests that consideration be given to temporarily discontinuing nursing or withholding the drug while nursing. This recommendation reflects that it is unknown whether the medication is excreted in human milk.

Q: Can I take Zalvor if I have a history of liver problems?

A: Official documents do not explicitly restrict the use of Zalvor in patients with hepatic (liver) impairment. The very minimal systemic absorption of the topical drug is generally consistent with a low expectation of significant systemic impact on the liver.

Q: Can I take Zalvor if I have kidney issues?

A: According to official product information, there are no explicit restrictions documented regarding the use of Zalvor in patients with renal (kidney) impairment. As a topical medication with low absorption, its potential impact on kidney function is generally not identified as a regulatory concern.

Q: Do the side effects of Zalvor usually go away on their own?

A: Many of the skin sensations experienced after application, such as burning or stinging, are generally mild and transient, meaning they go away quickly. Conversely, the original itching (pruritus) caused by the parasitic infestation may persist for up to four weeks even after successful treatment has cleared the parasites.

Q: Does Zalvor have a 'black box' warning from the FDA?

A: No official regulatory documents identify a Boxed Warning (often referred to as a 'black box' warning) for the Permethrin topical product. Safety information does detail contraindications for patients with known hypersensitivity.

Q: Is Zalvor used for short-term or long-term treatment?

A: The treatment is typically designed as a definitive, single-course application for the clearance of external parasitic infestations. It is generally intended as a short-term intervention, not a chronic or long-term therapy.

Q: Are there any specific laboratory tests required before or during Zalvor use?

A: Official prescribing information does not mandate specific laboratory tests for standard patient use. Although monitoring liver function was noted in the protocol for initial clinical trials, this is not a general requirement.

Q: Is Zalvor a type of antibiotic, or something else?

A: Zalvor is not an antibiotic. It is classified as an ectoparasiticide, which is a type of medicine specifically intended to combat parasites that infest the external surfaces of the body, such as the skin and scalp.

Q: Why is Zalvor only available by prescription?

A: The 5% cream formulation, typically used for scabies, is categorized as a prescription-only medicine (Rx) in the United States. In contrast, the 1% lotion formulation, often used for head lice, is typically available over-the-counter (OTC). The required status varies depending on the strength and specific use.

Q: Is there a generic version of Zalvor available?

A: Generic versions are commonly available. As the active ingredient is Permethrin, generic formulations are produced. These products are approved by regulatory agencies as therapeutically equivalent to the brand-name product.

Q: How long does Zalvor typically take to start working?

A: The medication is designed to kill the parasites upon contact. The critical time is how long the product must remain on the skin or hair for its maximum effect: 8 to 14 hours for scabies and 10 minutes for lice before rinsing.

Q: If I miss a dose of Zalvor, what is the usual recommendation?

A: Since the medicine is typically a single application treatment, there is no standard dosing schedule or instruction for a 'missed dose' in the traditional sense. A second application is generally only considered if live parasites are detected at least seven days after the first treatment.

Q: Are there any common over-the-counter medicines that interact with Zalvor?

A: Regulatory information indicates that no known significant systemic interactions are expected with common over-the-counter (OTC) medicines. This is due to the drug’s minimal absorption into the bloodstream, which is consistent with the expectation that it will not affect the systemic action of oral medicines.

Q: What happens if I stop taking Zalvor suddenly?

A: Since the treatment is typically a single course designed to be completed in one application, there are no instructions or warnings related to suddenly stopping use, unlike medications that are taken over a chronic period.

Q: Can Zalvor affect my ability to drive or operate machinery?

A: Post-marketing surveillance has reported dizziness as an adverse event in some patients. Patients are generally advised to be aware of this possibility when performing activities that require full attention, such as driving or operating machinery.

Q: Is Zalvor known to cause any long-term health issues?

A: The topical medication has very limited systemic absorption, typically two percent or less. Long-term human data on chronic effects of topical use were not found in public health databases, reflecting its use as a short-term, single-application product.

Q: Are there any specific foods or drinks I should avoid while using Zalvor?

A: Official labeling states that interactions with food or specific drinks are formally categorized as not established. This low risk is consistent with its topical administration rather than oral ingestion.

Q: Is there a risk of becoming dependent on Zalvor?

A: No. Zalvor is classified as an ectoparasiticide, and it is not identified as a controlled substance with a risk of dependence by regulatory agencies.

Q: Does Zalvor interact with alcohol?

A: Official labeling states that interactions with alcohol are formally categorized as not established. The labeling does not provide a specific regulatory warning about alcohol intake.

Q: Can Zalvor cause weight gain or weight loss?

A: Weight changes are not listed among the Common, Uncommon, or Not Known frequency adverse reactions reported in the official product labeling for human use. The reported side effects are primarily localized to the application site on the skin.

Q: Are there any known interactions between Zalvor and herbal supplements?

A: Official labeling states that interactions with herbal products are formally categorized as not established. The labeling states no specific interactions are established.

Q: What is the maximum duration Zalvor is typically used for?

A: The standard protocol involves a single application. If re-treatment is required, regulatory guidelines specify that it should be applied at a minimum interval of 7 days or more after the initial use.

Q: Can Zalvor affect my sleep?

A: While specific sleep disturbance is not a commonly listed adverse event, side effects such as fever and headache have been reported in post-marketing surveillance. These or other discomforts may indirectly affect sleep in some patients.

Q: Is Zalvor a controlled substance?

A: No. Regulatory agencies do not classify Zalvor as a controlled substance.

Q: What are the signs that Zalvor is working?

A: Success is indicated by the cessation of the parasitic infestation. It is important to note that the original itching caused by the parasites may temporarily increase after treatment and can persist for up to four weeks, even after the parasites have been cleared.

Q: Is it possible for Zalvor to stop working over time?

A: The drug’s efficacy can be constrained by the possibility of parasites developing resistance mechanisms. These mechanisms include changes that reduce the drug's affinity to the parasite's nerve cells or increased breakdown of the drug molecule.

Q: What are the ingredients in Zalvor besides the main active one?

A: The official regulatory labeling for the 5% cream lists the active ingredient, Permethrin, along with several inactive ingredients (excipients). These typically include butylated hydroxytoluene, glycerin, mineral oil, and purified water, which help stabilize the cream formulation.

Q: Does Zalvor affect blood pressure?

A: Blood pressure changes are not listed among the Common, Uncommon, or Not Known frequency adverse reactions reported in official product labeling for human use. The side effects are primarily localized to the skin application site.

Q: What is the typical timeframe for seeing research results for Zalvor?

A: Research studies on efficacy have included follow-up periods assessed over 52 weeks in long-term extensions. Earlier exploratory studies have observed changes in inflammatory biomarkers as early as week 2, though the clinical meaning of early biomarker changes requires further establishment.

Q: Can Zalvor interact with birth control pills?

A: Regulatory information indicates that no known significant systemic drug-drug interactions, including those with oral contraceptives (birth control pills), are expected. This is due to the drug’s minimal absorption into the bloodstream.

Q: What if I vomit shortly after taking a dose of Zalvor?

A: Zalvor is strictly a topical medicine intended for external use only on the skin or scalp. Since it is not taken orally, vomiting shortly after administration is not a relevant consideration for this drug.

Q: Does Zalvor need to be taken at the exact same time every day?

A: No. Since the treatment is typically a single application protocol, there is no need to adhere to a daily dosing schedule. The instructions focus on ensuring the required contact time (e.g., 8–14 hours) before washing off.

Q: Is it normal to experience stomach upset with Zalvor?

A: Stomach upset, including nausea, vomiting, abdominal pain, and diarrhea, has been reported as an adverse event in post-marketing surveillance. However, the most commonly reported side effects are reactions at the application site.

Q: Can people who are lactose intolerant take Zalvor?

A: The official list of inactive ingredients (excipients) for the 5% cream formulation does not include lactose. This information indicates that the 5% cream formulation is typically suitable for individuals with lactose intolerance.

Q: Does Zalvor have any reported psychiatric side effects?

A: Official labeling does not list specific psychiatric side effects. The common adverse effects are primarily related to skin irritation, such as itching, burning, and tingling at the application site.

How should Zalvor be stored and disposed of?

Official Storage and Disposal Requirements for Zalvor

This information is based on standard regulatory labeling requirements to ensure product stability and safety.

Requirement Area Official Statement (Placeholder)
Temperature & Protection Store below 25 C, protected from light and moisture.
Handling Do not freeze. Keep the product in the original, tightly closed container.
Stability Use within [X days] after initial opening or reconstitution, then discard.
Child Safety Keep Zalvor out of the sight and reach of children.
Disposal Do not flush unused or expired medicine down the toilet or throw it in household waste.

Proper storage is defined by regulatory documents through mandatory temperature and humidity controls to maintain the drug's efficacy until expiry. The labeling requires specific disposal methods, such as utilizing a pharmacy take-back program, to prevent environmental contamination and misuse, aligning with environmental protection guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zalvor found in:

A-Z Index: